Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
821
datasets available to search
ShareScore release 0.9.0
Dataset results
821 results for “anticoagulant”
Anticoagulation With Enhanced Gastrointestinal Safety (AEGIS) Trial
ClinicalTrials.gov study NCT05085405. IPD Sharing: NO. Countries: 1. Publications: 1.
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
ClinicalTrials.gov study NCT05712200. IPD Sharing: YES. Countries: 34. Publications: 0.
Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI
ClinicalTrials.gov study NCT04483583. IPD Sharing: NO. Countries: 1. Publications: 1.
Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers
ClinicalTrials.gov study NCT03864406. IPD Sharing: NO. Countries: 1. Publications: 3.
Reversal of Dabigatran Anticoagulant Effect With Idarucizumab
ClinicalTrials.gov study NCT02104947. IPD Sharing: Not stated. Countries: 33. Publications: 6.
A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)
ClinicalTrials.gov study NCT02329327. IPD Sharing: YES. Countries: 9. Publications: 7.
Citrate Anticoagulation in Renal Replacement Therapy: Impact of a High Post-filter Calcium Target on Efficacy
ClinicalTrials.gov study NCT05814341. IPD Sharing: YES. Countries: 1. Publications: 1.
Improving Anticoagulation Control in VISN 1
ClinicalTrials.gov study NCT01653405. IPD Sharing: NO. Countries: 1. Publications: 2.
Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters
ClinicalTrials.gov study NCT04066764. IPD Sharing: NO. Countries: 1. Publications: 10.
Anticoagulation in Post MI LV Thrombus Trial in Nepal
ClinicalTrials.gov study NCT05794399. IPD Sharing: NO. Countries: 1. Publications: 13.
Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation
ClinicalTrials.gov study NCT03795298. IPD Sharing: YES. Countries: 10. Publications: 1.
Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes
ClinicalTrials.gov study NCT02618577. IPD Sharing: Not stated. Countries: 18. Publications: 3.
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
ClinicalTrials.gov study NCT03080883. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO Trial
ClinicalTrials.gov study NCT04445935. IPD Sharing: UNDECIDED. Countries: 1. Publications: 2.
Implementing Prescriber-Pharmacist Collaborative Care for Evidence-based Anticoagulant Use
ClinicalTrials.gov study NCT05351749. IPD Sharing: NO. Countries: 1. Publications: 3.
Supplementary data for Kvist et. al. 2020 "Draft genome of the European medicinal leech Hirudo medicinalis (Annelida: Clitellata: Hirudiniformes) with emphasis on anticoagulants"
<p>anticoagulant_prots.tar.gz: Proteins sequence, alignment, exon structure, and tree files for identified anticoagulant proteins plus putative anticoagulant proteins from the Hirudo medicinalis ROM11733 v1 assembly</p> <p>Himedicinalis_ROM11733_annotation.tar.gz: InterProScan, UniProtKB, MAKER, RepeatModeller, Rfam, and tRNAscan-SE annotation files for the Hirudo medicinalis ROM11733 v1 assembly</p> <p>PhymmBL_tax_assign.tar.gz: PhymmBL files of the tree rounds of taxnonomic assignment</p>
Ionic Homeostasis, Acid-Base Balance and the Risk of Citrate Accumulation in Patients After Cardiovascular Surgery Treated with Continuous Veno-venous Haemofiltration with Post-Dilution Regional Citrate Anticoagulation.
<p>Data sets analyzed and described in the paper: "Ionic Homeostasis, Acid-Base Balance and the Risk of Citrate Accumulation in Patients After Cardiovascular Surgery Treated with Continuous Veno-venous Haemofiltration with Post-Dilution Regional Citrate Anticoagulation."</p>
Direct oral anticoagulants in atrial fibrillation patients with concomitant hyperthyroidism
Objective <p>Patients with hyperthyroidism were excluded from randomized clinical trials of direct oral anticoagulants(DOACs) for stroke prevention in patients with non-valvular atrial fibrillation (NVAF).</p> Methods <p>We performed a nationwide retrospective cohort study using data from the Taiwan National Health Insurance Research Database. We enrolled 3,213 and 1,181 NVAF patients with hyperthyroidism taking DOACs and warfarin, respectively, from June 1, 2012 to December 31, 2017. We also enrolled 53,591 and 16,564 NVAF patients without hyperthyroidism taking DOACs and warfarin, respectively. We used propensity score-based stabilized weights (PSSWs) to balance covariates across the study groups. We also used 1:4 matching on both taking DOACs, with (n=3,213) and without hyperthyroidism (n=12,852); and both taking warfarin, with (n=1,181) and without hyperthyroidism (n=4,724).</p> Results <p>After PSSW, DOAC had a comparable risk of ischemic stroke/systemic embolism (IS/SE) and a lower risk of major bleeding (hazard ratio (HR):0.65; [95% confidential interval (CI):0.44-0.96]; <i>P</i>=0.0295) than warfarin among patients with hyperthyroidism. There were comparable risks of IS/SE and major bleeding between those patients with and without hyperthyroidism. However, patients taking warfarin with hyperthyroidism had a lower risk of IS/SE than those without hyperthyroidism (HR:0.61; [95%CI:0.43-0.86]; <i>P</i>=0.0050).</p> Conclusion <p>Among NVAF Asian patients with concomitant hyperthyroidism, DOACs may be an effective and safer alternative to warfarin. Thromboprophylaxis with DOACs may be considered for such patients, and it is important to validate this finding in further prospective study.</p>
Direct oral anticoagulants in treatment of cerebral venous thrombosis: systematic review
Objectives Current guidelines do not recommend direct oral anticoagulants (DOAC) to treat cerebral venous thrombosis (CVT) despite their benefits over standard therapy. We performed a systematic review to summarize the published experience of DOAC therapy in CVT. Data sources MEDLINE, EMBASE, and COCHRANE databases up to November 18, 2020. Eligibility criteria All published articles of patients with CVT treated with DOAC were included. Studies without follow-up information were excluded. Data extraction and synthesis Two independent reviewers screened articles and extracted data. A risk of bias analysis was performed. Primary and secondary outcome measures Safety data included mortality, intracranial hemorrhage (ICH), or other adverse events. Efficacy data included recurrent CVT, recanalization rates, and disability by modified Rankin Scales (mRS). Results 33 studies met inclusion criteria. One randomized controlled trial, 5 observational cohorts, and 27 case series or studies reported 279 patients treated with DOAC for CVT: 41% dabigatran, 47% rivaroxaban, 10% apixaban, and 2% edoxaban, in addition to 315 patients treated with standard therapy. The observational cohorts showed a similar risk of death in DOAC and standard therapy arms (RR 2.12, 95%CI 0.29-15.59). New ICH was reported in 2 (0.7%) DOAC-treated patients and recurrent CVT occurred in 4 (1.5%). A favourable mRS between 0 and 2 was reported in 94% of DOAC-treated patients, more likely than standard therapy in observational cohorts (RR 1.13, 95% CI: 1.02-1.25). Conclusion The evidence for DOAC use in CVT is limited although suggests sufficient safety and efficacy despite variability in timing and dose of treatment. This systematic review highlights that further rigorous trials are needed to validate these findings and to determine optimal treatment regimens. PROSPERO ID: CRD42017078398
Risk for excessive anticoagulation during hemodialysis is associated with type of vascular access and bedside coagulation testing: Results of a cross-sectional study
<p>Anonymized dataset of the cross-sectional study assessing (i) heparin dosing within a prevalent hemodialysis cohort, (ii) the anticoagulant effects of the heparinization strategy and (iii) identifying predictive factors of the heparin dosing regimen.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.